SPATS2 is correlated with cell cycle progression and immune cells infiltration in hepatocellular carcinoma.
Cell cycle
Hepatocellular carcinoma
Immune infiltration
SPATS2
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
11 Jan 2023
11 Jan 2023
Historique:
received:
27
09
2022
accepted:
22
12
2022
entrez:
11
1
2023
pubmed:
12
1
2023
medline:
14
1
2023
Statut:
epublish
Résumé
The spermatogenesis associated serine rich 2 (SPATS2) is a member of RNA-binding protein in which the abnormal expression is linked with carcinogenesis in serval types of cancer. However, there is no systematic study on the differential expression, prognostic significance, epigenetic regulation, immune infiltration of SPATS2 in hepatocellular carcinoma (HCC). In the present study, we investigated the expression, prognosis, epigenetic regulation, and immune cell infiltration of SPATS2 in HCC. We found that the elevated expression of SPATS2 was unfavorably associated with the clinical pathological stage and prognosis. Functional enrichment analysis revealed that SPATS2 is associated with cell cycle, apoptosis and cancer cell metastasis processes in HCC. Our results confirmed that knockdown of SPATS2 will affect cell cycle, apoptosis and invasion of HCC cell lines. Moreover, the expression of SPATS2 is upregulated by epigenetic regulation, including DNA methylation, m6A and histone modification in HCC. In addition, SPATS2 expression was positively correlated with immune cell infiltration or expression of immune related gene markers in HCC. Taken together, our data demonstrated that SPATS2 is associated with progression and immune infiltration, and could serve as a prognostic biomarker for HCC. In conclusion, these results highlight the potential of SPATS2 to be used as a therapeutic target for HCC.
Identifiants
pubmed: 36631750
doi: 10.1186/s12876-022-02633-y
pii: 10.1186/s12876-022-02633-y
pmc: PMC9832668
doi:
Substances chimiques
SPATS2 protein, human
0
Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8Subventions
Organisme : National Natural Science Foundation of China
ID : 81660024
Organisme : Natural Science Foundation of Inner Mongolia
ID : 2020MS08096
Organisme : Inner Mongolia Autonomous Region Science and Technology Innovation Guidance Project
ID : KCBJ2018021
Informations de copyright
© 2023. The Author(s).
Références
Cancers (Basel). 2019 Dec 27;12(1):
pubmed: 31892230
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Oncoimmunology. 2017 Aug 16;6(11):e1356965
pubmed: 29147615
Exp Ther Med. 2021 Jul;22(1):698
pubmed: 33986862
Cancers (Basel). 2019 Apr 19;11(4):
pubmed: 31010242
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancers (Basel). 2022 Aug 20;14(16):
pubmed: 36011021
Bioinformatics. 2019 Oct 15;35(20):4200-4202
pubmed: 30903160
Medicine (Baltimore). 2020 Feb;99(9):e19230
pubmed: 32118724
Bioinformatics. 2018 Nov 1;34(21):3771-3772
pubmed: 29790900
BMC Cancer. 2016 Sep 29;16(1):760
pubmed: 27681076
Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):525-543
pubmed: 33850328
Front Cell Dev Biol. 2021 Nov 12;9:775462
pubmed: 34869376
Clin Liver Dis. 2023 Feb;27(1):85-102
pubmed: 36400469
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Curr Treat Options Oncol. 2021 Aug 23;22(10):87
pubmed: 34424422
Front Immunol. 2022 Feb 23;13:846923
pubmed: 35281021
Front Immunol. 2021 Dec 02;12:793343
pubmed: 34925377
J Cancer. 2021 Jan 1;12(1):89-98
pubmed: 33391405
Nat Commun. 2016 Dec 22;7:13875
pubmed: 28004750
Cell Death Dis. 2020 Oct 9;11(10):837
pubmed: 33037180
Am J Reprod Immunol. 2022 May;87(5):e13537
pubmed: 35263479
Cell. 2017 Jun 15;169(7):1342-1356.e16
pubmed: 28622514
Gastroenterology. 2013 Mar;144(3):512-27
pubmed: 23313965
Crit Care Nurs Clin North Am. 2022 Sep;34(3):289-301
pubmed: 36049848
Biochem Biophys Res Commun. 2002 Apr 12;292(4):992-8
pubmed: 11944913
Curr Opin Oncol. 2022 Mar 1;34(2):155-160
pubmed: 34923550
Gastroenterology. 2008 Jul;135(1):234-43
pubmed: 18485901
J Immunother Cancer. 2019 Nov 29;7(1):331
pubmed: 31783783